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0959-8049/ª 2018 Elsevier Ltd. All righAbstract Objectives: Few empirical analyses of the impact of organised prostate cancer
(PCa) screening on healthcare costs exist, despite cost-related information often being consid-
ered as a prerequisite to informed screening decisions. Therefore, we estimate the differences in
register-based costs of publicly funded healthcare in the two arms of the Finnish Randomised
Study of Screening for Prostate Cancer (FinRSPC) after 20 years.
Methods: We obtained individual-level register data on prescription medications, as well as
inpatient and outpatient care, to estimate healthcare costs for 80,149 men during the first
20 years of the FinRSPC. We compared healthcare costs for the men in each trial arm and
performed statistical analysis.
Results: For all men diagnosed with PCa during the 20-year observation period, mean PCa-
related costs appeared to be around 10% lower in the screening arm (SA). Mean all-cause
healthcare costs for these men were also lower in the SA, but differences were smaller than
for PCa-related costs alone, and no longer statistically significant. For men dying from
PCa, although the difference was not statistically significant, mean all-cause healthcare costs
were around 10% higher. When analysis included all observations, cumulative costs were
slightly higher in the CA; however, after excluding extreme values, cumulative costs were
slightly higher in the SA.N. Booth).
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N. Booth et al. / European Journal of Cancer 93 (2018) 108e118 109Conclusions: No major cost impacts due to screening were apparent, but the FinRSPC’s 20-
year follow-up period is too short to provide definitive evidence at this stage. Longer term
follow-up will be required to be better informed about the costs of, or savings from, intro-
ducing mass PCa screening.
ª 2018 Elsevier Ltd. All rights reserved.1. Introduction
Although there is some evidence of the effectiveness of
organised screening in reducing prostate cancer (PCa)
mortality [1], there has been a dearth of published
empirical analyses of the actual impact of such mass
screening on healthcare costs in real-world settings.
Prostate-specific antigen (PSA)ebased screening poten-
tially provides a means of altering the clinical course of
the PCa and thereby improving prognosis and outcomes
[2]. However, a presumption is often made that early
intervention will reduce overall healthcare costs ([2e4]),
and this presumption should be assessed, ideally
through a pragmatic randomised controlled trial (RCT)
([5,6]). The primary objective of this analysis is to
compare register-based healthcare cost estimates be-
tween the two arms of the Finnish Randomised Study of
Screening for Prostate Cancer (FinRSPC), primarily
using intention-to-screen (ITS)danalysis after a
maximum of 20 years of follow-up.
2. Methods
2.1. Participants and intervention
Although the European Randomized study of Screening
for Prostate Cancer (ERSPC) offers comparable data
from each participating centre on outcome measures
such as PCa mortality [1], it is unlikely that the ERSPC
can offer comparable data on healthcare costs, as costs
are known to be dependent on the healthcare system in
question [7]. Given such differences in cost accounting
and costs even within Europe, and the well-established
registers of healthcare cost-related information in
Finland, our study is restricted to the FinRSPC, which
contributes the largest number of trial participants to
the ERSPC. The analysis of healthcare costs presented
here is carried out as part of the FinRSPC, the primary
objective of which is to investigate the impact of mass
PSA-screening on PCa mortality [8]. Secondary objec-
tives of the FinRSPC include the investigation of the
trial’s impact on costs and health-related quality of life,
and then the combination of these sources of informa-
tion to provide information on cost-effectiveness [9].
The target population of the FinRSPC was selected
from the Finnish population registry and consists of
men born in 1929e1944 and residing in the Helsinki orTampere region during the recruitment period
(1996e99, total randomised n Z 80,458). The main
exclusion criterion was PCa-diagnosis before the date of
randomisation (this information was obtained from the
Finnish Cancer Registry, [FCR]). Further details about
the study design can be obtained from Booth et al. [10].
The men in the screening group (screening arm, SA)
were invited to the screening test (serum PSA) at a local
clinic. The men in the reference group (control arm, CA)
received no invitation as part of the trial.3. Materials and analytical methods
The research protocol for the present study was
approved by Finnish data-protection authorities and by
the National Institute for Health and Welfare (THL).
The protocol was also reviewed by the Tampere Uni-
versity Hospital Ethics committee (reference number
R05053). After receiving study approval, we were
permitted to collate and link the data supplied by a
number of registries to the FinRSPC database, using
each man’s unique Finnish personal identity code for
retrieval. This study was undertaken in close co-
operation with the FCR, with resources and expertise
from the FCR helping to create, maintain, and improve
the FinRSPC trial database and its links with the FCR’s
cancer register [11]. The main data sources used in this
study are described in the Appendix: these are the
FinRSPC trial database, the Care Register for Health
Care (CRHC) and the prescription-medicine reim-
bursement register (PMRR). The costs of the screening
intervention have been estimated to be approximately 50
Euros per screen (including the organisation of the
invitation, the drawing of the blood sample and the PSA
determinations), and this figure is used in all analyses.
All total or average Euro amounts we report in our re-
sults are rounded to the nearest 100 Euros, as this gives
a suitable level of precision for these cost estimates. The
information on screening and healthcare costs from all
the above sources is specific to each man in the trial and
the date of each cost item is also recorded. PCa-related
costs could be identified using the PCa identifier avail-
able in the PMRR and, in the case of the CRHC data,
using the ICD-10 code C61. We followed cost-analysis
guidelines for the analysis of costs ([14e17]) and
examined differences between the arms using two-sided
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priate to confirm the robustness of our results [18].
4. Results
Altogether, there were 31,867 men in the SA and 48,282
men in the CA (Fig. 1). Cost-related data were recorded
in at least one of the registers used for 48,097 men in the
CA (100%) and 31,753 men in the SA (100%). Cost re-
cords were not found for 198 men in the CA and for 119
men in the SA. These men may not have used hospital
care or may not have been reimbursed for prescription
medications during this follow-up period. No records
from either register were found for one man in the SAFig. 1. Flowchart illustrating the groups for whichwho was diagnosed with, and subsequently died of, PCa.
The frequencies of primary treatments were as follows:
surgery (SA 26%, CA 19%), radiotherapy (SA 35%, CA
40%), endocrine treatment (SA 15%, CA 20%) and
expectant management (SA 23%, CA 18%), with pri-
mary treatment missing for 1e2% of men in each arm.
After 20 years of follow-up, healthcare costs were
around 40% higher on average for men diagnosed with
PCa, and around 70% higher on average for men who
died from PCa, compared with all men in the trial
(Table 1). The mean healthcare costs of the 80,149 men
in the FinRSPC did not differ markedly between the
arms, but a statistically significant difference, with lower
costs in the CA, was observed when ‘extremeregister-based healthcare costs are estimated.
Table 1
Comparisons and statistical tests of the cost estimates.
Estimated register-based
healthcare costs
Median in CA (IQR in CA) Median in SA (IQR in SA) Mean in CA Mean in SA Difference between
means (standard error)
Two-sided
t-test
Cohen’s
d
effect size
Mean in SA,
according to mode
of detection
All-cause cost estimates for all men
in the trial
24,900 V (32,700 V) 25,400 V (33,000 V) 36,500 V 36,300 V L200 V (400 V) p Z 0.64 <0.01 N.R.
All-cause cost estimates for all men
in the trial
(excluding ‘extreme’
observationsy)
24,900 V (32,700 V) 25,400 V (33,000 V) 31,800 V 32,200 V 400 V (200 V) p < 0.05 z0.01 N.R.
All-cause cost estimates for
diagnosed men
39,200 V (42,500 V) 38,800 V (40,500 V) 51,900 V 51,300 V L600 V (1100 V) p Z 0.59 z0.01 SD: 50,300 V
CD: 52,000 V
PCa-related cost estimates for
diagnosed men
8800 V (12,800 V) 7700 V (12,600 V) 15,300 V 14,200 V L1100 V (400 V) p < 0.01 z0.06 SD: 14,700 V
CD: 13,800 V
PCa-related cost estimates for
men with low-riskyy
tumour at diagnosis
5900 V (9700 V) 5700 V (8900 V) 11,600 V 11,000 V L600 V (600 V) p Z 0.35 z0.04 SD: 11,400 V
CD: 10,200 V
PCa-related cost estimates for
men with
intermediate-risk tumour at
diagnosis
8100 V (9400 V) 7800 V (10,100 V) 13,200 V 13,400 V 200 V (700 V) p Z 0.76 z-0.01 SD: 15,000 V
CD: 12,500 V
PCa-related cost estimates for
men with high-risk
tumour at diagnosis
12,300 V (17,700 V) 11,800 V (18,700 V) 20,600 V 20,400 V L200 V (1000 V) p Z 0.85 <0.01 SD: 24,500 V
CD: 18,400 V
PCa-related cost estimates for
men with metastatic
tumour at diagnosis
15,000 V (25,100 V) 15,600 V (26,100 V) 23,900 V 24,000 V 100 V (2000 V) p Z 0.94 >0.01 SD: 36,000 V
CD: 21,900 V
PCa-related cost estimates for
men with tumour
information missing at
diagnosis
6800 V (7800 V) 7400 V (9200 V) 8500 V 8500 V 0 V (800 V) p Z 0.95 <0.01 SD: 6500 V
CD: 8500 V
All-cause cost estimates for men
who have died from PCa
47,600 V (57,100 V) 51,900 V (53,400 V) 60,000 V 65,100 V 5100 V (4600 V) p Z 0.27 z0.08 SD: 71,000 V
CD: 62,400 V
PCa-related cost estimates for men
who have died from PCa
22,100 V (35,600 V) 23,600 V (38,600 V) 31,400 V 33,000 V 1700 V (2100 V) p Z 0.43 z0.05 SD: 43,700 V
CD: 27,900 V
Abbreviations: CA, control arm; SA, screening arm; IQR, interquartile range; N.R., Not relevant SD, PCa detected via the screening intervention; CD, clinically detected PCa.
y The cut-off point for extreme observations used was: 3rd quartile þ (3*IQR).
yy We used the stage classification used by the European Randomized Study of Screening for Prostate Cancer (ERSPC) [1].
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Fig. 2. All-cause cost estimates of healthcare and medications between 1996 and 2016 for all men in the trial (N Z 80,149) by arm,
cumulative average costs adjusted to the size of each trial arm.
N. Booth et al. / European Journal of Cancer 93 (2018) 108e118112observations’ were excluded from our analysis (Table 1).
However, the difference between the two arms in terms
of cumulative all-cause costs appears to be small
(Fig. 2). Further, all-cause healthcare costs for men
diagnosed with PCa, adjusted for the number of men in
each arm, were higher in the SA, with a steadily
increasing differential (Fig. 3). Similarly, higher PCa-
related cost estimates were seen for diagnosed men in
the SA, with noticeable differences at follow-up years 1,Fig. 3. All-cause cost estimates of healthcare and medications between
by arm, cumulative average costs adjusted to the size of each trial arm4 and 8 (corresponding to the screening rounds; Fig. 4).
For healthcare costs of men who died from PCa during
the follow-up, the difference increased after follow-up
years 5 and 10 (corresponding to a year or more after
the first and second screening rounds), with higher costs
for the SA (Fig. 5). Similar findings were obtained when
the graph for the men who eventually died from PCa
was restricted to focus only on PCa-related average
costs (Fig. 6). In Table 1, we also use the risk1996 and 2016 for men diagnosed with prostate cancer in the trial
.
Fig. 4. Prostate cancer -related cost estimates of healthcare and medications between 1996 and 2016 for men diagnosed with prostate
cancer by arm, cumulative average costs adjusted to the size of each trial arm.
Fig. 5. All-cause cost estimates of healthcare and medications between 1996 and 2016 for the men who have died from prostate cancer,
cumulative average costs per man who died from prostate cancer in each trial arm.
N. Booth et al. / European Journal of Cancer 93 (2018) 108e118 113classification utilised by the ERSPC to show how the
PCa-related cost estimates for all diagnosed men vary
with risk-stage at diagnosis. When comparing average
PCa-related cost estimates for all diagnosed men, there
is a statistically significant difference, with the SA
incurring lower costs. However, this result is not
observed for all the separate risk-stage subgroups. The
mean cost estimates for PCa-related healthcare for men
with low-risk, intermediate-risk, high-risk, or metastatictumours at diagnosis and those for men with tumour
information missing at diagnosis, although not statisti-
cally significant, are either higher for the CA, higher for
the SA, or do not show differences in mean costs. As an
adjunct to the ITS analysis, for the SA, we report the
mean costs for both those prostate cancers detected due
to screening (SD) and for clinically detected PCa (CD;
Table 1). The effect sizes presented indicate that the
comparison of PCa-related costs for men who died from
Fig. 6. Prostate cancer -related cost estimates of healthcare and medications between 1996 and 2016 for the men who have died from
prostate cancer, cumulative average costs per man who died from prostate cancer in each trial arm.
N. Booth et al. / European Journal of Cancer 93 (2018) 108e118114PCa has the largest effect size (i.e., substantive signifi-
cance, as indicated by the Cohen’s d -measure), although
this comparison of means did not achieve conventional
levels of statistical significance (Table 1).
5. Discussion
For all men diagnosed with PCa, screening reduced
mean PCa-related costs (by around 1100V, or less than
10% [see Table 1]). However, classification of PCa-
related costs by risk-stage at diagnosis indicates that
this result may be subject to a ‘reversal paradox’ [19],
whereby this overall result may not faithfully represent
the direction or size of each of the risk-stage subgroups.
Further, for all diagnosed men, the reduction in mean
all-cause healthcare costs was less than when focussing
on PCa-related costs alone (i.e., around 700V, or
around 1%). In addition, cumulative PCa-related
healthcare cost estimates for these same diagnosed
men, adjusted for the number of men in each trial arm,
were slightly higher in the SA (around 100V, or less than
10% [see Fig. 4]).
Two important issues need to be considered when
interpreting all our findings, first and foremost, the
sample size required to show statistically significant re-
sults, second, opportunistic PSA testing (also known as
contamination). First, the statistical power calculations
for the FinRSPC are based on the primary outcome of
disease-specific mortality. Therefore, the FinRSPC is
not powered to evaluate all-cause costs, any more than it
is suitably powered to detect differences in all-cause
mortality, as only a minority of total mortality is
directly related to PCa. In addition, the original sample-size estimates would likely need to be at least doubled to
take into account the unexpected levels of contamina-
tion encountered in the trial [20], alternatively, the
duration of follow-up would need to be extended
beyond 20 years. Further, the comparisons of the rela-
tively small subgroup of men who died from PCa
(N Z 925) have fairly low precision given the observed
heterogeneity in costs between patients. Second, unor-
ganised or non-systematic PSA-testing can dilute the
observed effect of the mass-screening intervention.
Instead of the comparator being a complete absence of
screening, the comparator in the FinRSPC is less
organised and less systematic screening. Widespread
contamination likely dilutes PCa-mortality benefit, any
differences in health-related quality of life, as well as the
differences in costs observed here. Therefore, our results
should be interpreted against the possibility of high
levels of contamination in the CA, reflected for instance
in the high cumulative incidence of T1c cancers (i.e.,
impalpable cancers detectable only by PSA testing [21])
in the CA, with a cumulative incidence of 4.5% in the
CA and 6.1% in the SA [22].
It should also be noted that for men diagnosed with
PCa, the overall costs were higher for the SA than for the
CA, when adjusted for the size of each trial arm (Figs. 3
and 4), even though the mean healthcare costs for all
men diagnosed with PCa were lower in the SA (Table 1).
Importantly, these all-cause cumulative cost differentials
could be explained by men with indolent disease being
followed up clinically over extensive periods of time due
to overdiagnosis. These cases could also involve some
lead-time, increasing total costs. Similarly, the higher
mean PCa-related costs in the SA men who died from
N. Booth et al. / European Journal of Cancer 93 (2018) 108e118 115PCa could be due to some of these first 925 recorded PCa
deaths including some of the more aggressive and rapidly
progressing cancers. Precision medicine, with treatment
tailored to the underlying molecular aberrations, holds
promise for treating advanced PCa, but such in-
terventions are currently at a largely experimental stage
and not widely used. Targeted treatment has the poten-
tial to change the economic impact of screening, but
currently it is impossible to predict whether early detec-
tion by screening will allow definitive treatment (with its
potential for cost savings, increased life expectancy or
improved quality of life), or merely delay disease pro-
gression (with its potential for increasing costs or
decreased quality of life). In large part, any impact on
costs will depend on both the differences in the time
patients live with advanced PCa, as well as on the relative
mortality, between the two trial arms.
One further interpretation of our risk-stage subgroup
analysis and analysis of screen-detected versus clinically
detected PCa (Table 1, and from other analyses not re-
ported here due to restricted space) suggests men in the
SA diagnosed via PSA-screening could have received
more systematic care, or just more care in general, than
those men in the CA. Analysis suggests that mean all-
cause healthcare costs were lower for men with screen-
detected PCa than for men in the screening arm over-
all, and lower for men with screen-detected low-risk
tumour at diagnosis than for men in the screening arm
overall. However, for all other diagnosed men, mean
healthcare costs were higher amongst men with screen-
detected prostate cancer than for men in the screening
arm overall. Furthermore, the increasing differential
observed in all-cause cost estimates for men diagnosed
with PCa could also be explained by the screening
intervention resulting in an increased awareness of
health issues, or simply an increased supply of, or de-
mand for, health services not directly related to PCa.
5.1. Strengths of the study
The novelty of our results is emphasised by the fact that
a systematic literature search failed to identify studies
reporting the analysis of real-world data on PCa-
screeningerelated healthcare costs from any RCT,
despite finding a number of studies on related topics
(e.g. [23e31]).
Modelling studies, such as those found during our
systematic search, offer estimates or forecasts of costs
which are based on assumptions, which often, in turn,
are based on modelled estimates of primary or second-
ary outcomes. On the other hand, our analysis describes
the cost data recorded on the basis of observed out-
comes. Such description will have relevance for eco-
nomic evaluation using data from other ERSPC
countries to the extent that, e.g., trial protocols are
comparable. For this reason, despite only being from
one participating centre in the ERSPC, our results maystill be highly indicative of the relative difference in costs
between the trial arms in other European countries. We
were able to apply ITS analysis on a large and repre-
sentative population over a 20-year period, with fairly
comprehensive data on costs of hospital-care and pre-
scription medication use and, hence, obtain accurate
and potentially generalisable cost estimates. Further,
our data-driven approach requires few assumptions
concerning costs or outcomes for the men followed up in
the FinRSPC over 20 years. Our data also capture most
costs arising from the major disadvantage of PSA
screening, i.e., the overdiagnosis of indolent PCa. This is
evidenced by, e.g., the overall costs due to PCa being
higher in the SA than in the CA (Figs. 3 and 4), despite
men in the SA having lower PCa-related mean costs
(Table 1). Although the precision of our results is
adversely affected by the observed heterogeneity in
costs, we have extensive observations from a publicly
funded and centralised healthcare system, with highly
comparable data over the study period.
5.2. Limitations of the study
First, our study covers a period which included major
changes in PCa-treatment protocols. However, this
limitation would be true of any pragmatic study in this
field. The CRHC does not always provide sufficient in-
formation on procedures to provide precise details of all
treatments for all periods; therefore, we reported the
frequencies of primary treatments using the high-quality
FinRSPC trial database. Secondly, we were unable to
cover primary healthcare costs because, until recently
(2014), no national primary healthcare registers or da-
tabases existed in Finland. Although data including
primary-care costs were collected using questionnaires
alongside the FinRSPC [10], that questionnaire data
do not provide comparable data to the data used in this
register-based study. However, the main responsibility
for PCa management is with tertiary care, including the
most expensive therapeutic procedures. A related limi-
tation is the possibly limited applicability of our analysis
outside the context of countries with mainly publicly
funded healthcare. Third, consistent cost weights were
not available for each year during our study period.
Although we used the 2009 cost weights for all years,
and these weights were not adjusted in any way, not
accounting for health-sector inflation and not under-
taking discounting, it seems unlikely that this would
have a large negative impact on the policy relevance of
our study. Any such adjustments to the cost estimates
would likely affect the two arms equally [32], and our
choice to round these estimates to the nearest 100V is
likely to negate any such adjustments in any case [33].
Perhaps most importantly, we have attempted to present
costs in an appropriate manner for a policy-oriented
readership. Unfortunately, no robust method seems to
exist to extrapolate the observed cost estimates from
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from PCa in the coming years [34]. A related limitation
is that although potentially declining during the study
period, overdiagnosis or overtreatment may still be one
contributing factor in our results [35]. Despite such
limitations, our estimates are expected to be indicative
and representative of the main costs drivers in a publicly
funded healthcare system, even though they do not
represent the exact costs of all services used as a result of
screening. Further, the analysis presented here does not
provide a definitive assessment of the impact of costs on
PSA-based mass screening. The full impact of screening
on healthcare costs will only be clear after all the men
are deceased, and the FinRSPC cohort is relatively
immature in this respect (63% of men are still alive). Of
all men, 1.2% had died from PCa during the 20-year
follow-up period, whereas the expectation is that PCa
mortality will eventually reach over 2% in this popula-
tion [2].
6. Conclusion
No major cost impacts due to screening were apparent,
but after 20 years of follow-up, the FinRSPC trial shows
that for all diagnosed men, mean PCa-related costs were
lower in the screening arm. However, in addition, mean
healthcare costs for the men who died from PCa appear
to be substantively higher in the screening arm. These
estimates of differences in mean healthcare costs should
be interpreted in the light of low statistical power, the
effects of PSA-contamination within the trial, and with
the knowledge that these estimates of average costs may
be impacted by extreme observations and cover up dif-
ferences between risk subgroups. In conclusion, the 20-
year follow-up of this large cohort is too short to give
definitive evidence about the healthcare costs of PSA
screening. Longer term follow-up will be required to be
better informed about the costs of, or savings from,
introducing PSA-based mass screening.
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Appendix
The FinRSPC trial database contains information about
all PCa diagnoses before 2015 obtained from the
nationwide Finnish Cancer Registry, (FCR). The FCR
has been shown to have comprehensive coverage of all
solid cancers diagnosed in Finland [12], but these di-
agnoses data from the FCR were also confirmed from
medical records as part of the FinRSPC. This trial
database also includes data from Statistics Finland’s
Causes-of-death statistics (available from: https://www.
stat.fi/til/ksyyt/index_en.html), which has, since the
start of the FinRSPC in 1996, applied the 10th
revision of the International Classification of Diseases
(ICD-10). For a sample of men from the FinRSPC,
the official causes of death were reviewed by an
independent expert review panel and found to be in
close agreement (overall agreement 98%, k Z 0.95)
[13]. For the period of the study (1996e2016), the two
main registers containing information on healthcare
utilisation and costs were the CRHC and the PMRR, i.
e., the Care Register for Health Care (“Hilmo” in
Finnish, produced by THL) and the Prescription-
Medicine Reimbursement Register (“La¨a¨keostotiedot”
in Finnish, produced by the Social Insurance Institution
of Finland [Kela]). Since 2010, the CRHC has consis-
tently included records of both outpatient and inpatient
visits to both secondary and tertiary health care. The
interested reader can refer to https://www.thl.fi/en/web/
thlfi-en/statistics/information-on-statistics/register-
descriptions/care-register-for-health-care for further
details on the CRHC. Before 2010, only inpatient
records were available from the CRHC, so for this
earlier period, we used all available outpatient records
N. Booth et al. / European Journal of Cancer 93 (2018) 108e118 117collated by the two hospital administrations in the
districts of Pirkanmaa and Uusimaa. On the advice of
the producers of the CRHC, the 2009 Nordic
diagnosis-related groups (NordDRG) classification sys-
tem is used here for inpatient care episodes before 2010.
For episodes in 2010 and later, the 2015 NordDRG
classifiers are used. Whenever it is possible to calculate a
NordDRG-based cost for both inpatient and outpatient
costs, the 2009 NordDRG costing weights are applied.
When this is not possible (in a few instances and largely
before 2010), we use the municipal billing records from
the administrative databases in the hospital districts of
Pirkanmaa and Uusimaa to estimate the costs. The
PMRR contains the exact costs of prescription medi-
cations sold through retail pharmacies but does not
include information on prescription medications sup-
plied by hospital pharmacies. Another restriction of the
nationwide PMRR is that information limited to only
those prescription medications reimbursed under the
Health Insurance Act at any point in time. The inter-
ested reader can refer to http://www.kela.fi/web/en/
inclusion-of-medicines for further information on the
reimbursement status of medicines.References
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